| Issue Date |
Title |
Author(s) |
| 2016 |
Analysis of the Impact Factor of Emergency Medicine Journals in the Past 10 Years |
Liang, Yang;Ge, Hong-Xia;Ma, Qing-Bian |
| 9-Apr-2021 |
Castor Oil-Based Bioplastics via Polyesterification: Synthesis, Characterization, and Functionalization |
Pan, Jun-Lin;Xu, Chu-Ran;Zeng, Fu-Rong;Liang, Yang;Zhang, Tao;Xu, Jing;Li, Zi-Long;Li, Zi-Chen |
| Jul-2022 |
Drug resistance biomarker ABCC4 of selinexor and immune feature in multiple myeloma |
Hu, Fang;Chen, Xiao-Qin;Li, Xue-Ping;Lu, Yu-Xiu;Chen, Si-Liang;Wang, Da-Wei;Liang, Yang;Dai, Yu-Jun |
| 18-Aug-2022 |
Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial |
Jiang, Qian;Li, Zongru;Qin, Yazhen;Li, Weiming;Xu, Na;Liu, Bingcheng;Zhang, Yanli;Meng, Li;Zhu, Huanling;Du, Xin;Chen, Suning;Liang, Yang;Hu, Yu;Liu, Xiaoli;Song, Yongping;Men, Lichuang;Chen, Zi;Niu, Qian;Wang, Hengbang;Lu, Ming;Yang, Dajun;Zhai, Yifan;Huang, Xiaojun |
| 31-Oct-2022 |
Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial (vol 15, 113, 2022) |
Jiang, Qian;Li, Zongru;Qin, Yazhen;Li, Weiming;Xu, Na;Liu, Bingcheng;Zhang, Yanli;Meng, Li;Zhu, Huanling;Du, Xin;Chen, Suning;Liang, Yang;Hu, Yu;Liu, Xiaoli;Song, Yongping;Men, Lichuang;Chen, Zi;Niu, Qian;Wang, Hengbang;Lu, Ming;Yang, Dajun;Zhai, Yifan;Huang, Xiaojun |
| 20-Feb-2023 |
Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial (vol 15, 159, 2022) |
Jiang, Qian;Li, Zongru;Qin, Yazhen;Li, Weiming;Xu, Na;Liu, Bingcheng;Zhang, Yanli;Meng, Li;Zhu, Huanling;Du, Xin;Chen, Suning;Liang, Yang;Hu, Yu;Liu, Xiaoli;Song, Yongping;Men, Lichuang;Chen, Zi;Niu, Qian;Wang, Hengbang;Lu, Ming;Yang, Dajun;Zhai, Yifan;Huang, Xiaojun |
| 2017 |
Performance of Simplified Acute Physiology Score 3 in Predicting Hospital Mortality in Emergency Intensive Care Unit |
Ma, Qing-Bian;Fu, Yuan-Wei;Feng, Lu;Zhai, Qiang-Rong;Liang, Yang;Wu, Meng;Zheng, Ya-An |
| Aug-2022 |
A prognostic survival nomogram for persons with extra-nodal natural killer-/T-cell lymphoma |
Wang, Hua;Fu, Bi-bo;Wuxiao, Zhi-jun;Li, Ya-jun;Huang, Li;Ma, Jie;Zhai, Zhi-min;Guo, Jing;Wu, Yuan-bin;Xu, Zhen-shu;Feng, Jia;Zhou, Sheng-sheng;Chen, Ting-ting;Chen, Xing-gui;Li, Guo-wei;Liu, Ting-zhi;Huang, Hai-bin;Zheng, Run-hui;Li, Yong-hua;Tao, Hong-fang;Zi, Fu-ming;Wu, Fan;Wang, Juan;Zeng, Hui;Fu, Cai-bo;Gale, Robert Peter;Xia, Zhong-jun;Liang, Yang |
| 23-Nov-2021 |
Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL1 (T315I)-Mutated Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) |
Qian, Jiang;Shi, Dayu;Li, Zongru;Hou, Yue;Hu, Yu;Li, Weiming;Liu, Xiaoli;Xu, Na;Song, Yongping;Zhang, Gongli;Meng, Li;Hong, Zhenya;Liu, Bingcheng;Li, Yan;Chen, Suning;Xue, Mengxing;Zhu, Huanling;Li, He;Du, Xin;Lou, Jin;Zhang, Xiaohan;Liang, Yang;Dai, Yujun;Chen, Zi;Niu, Qian;Men, Lichuang;Yang, Dajun;Zhai, Yifan;Huang, Xiaojun |
| 15-Nov-2022 |
Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) with T315I Mutation |
Jiang, Qian;Li, Zongru;Hou, Yue;Hu, Yu;Li, Weiming;Liu, Xiaoli;Xu, Na;Zhang, Yanli;Song, Yongping;Meng, Li;Hong, Zhenya;Liu, Bingcheng;Li, Yan;Chen, Suning;Xue, Mengxing;Zhu, Huanling;Li, He;Du, Xin;Lou, Jin;Zhang, Xiaohan;Liang, Yang;Dai, Yu-Jun;Chen, Zi;Niu, Qian;Men, Lichuang;Yang, Dajun;Zhai, Yifan;Huang, Xiao-Jun |
| 1-Dec-2020 |
Using machine learning tools to predict outcomes for emergency department intensive care unit patients |
Zhai, Qiangrong;Lin, Zi;Ge, Hongxia;Liang, Yang;Li, Nan;Ma, Qingbian;Ye, Chuyang |
